Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely
and effectively reduce craving for opioids in patients with opioid use disorder, a primary
factor contributing to early relapse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)